Purchasing channels for Brivaracetam/Brivaracetam after they are launched in the country

Brivaracetam/Brivaracetam is a new anti-epileptic drug mainly used to treat partial-onset epilepsy in adults and adolescents. The drug regulates neuronal signaling by highly selectively binding to the synaptic vesicle protein 2A (SV2A) receptor, thereby effectively inhibiting epileptic seizures. As the need for personalized treatment of epilepsy increases, brivaracetam has attracted attention because of its fewer side effects and good tolerability. Regarding the listing and purchase of this drug in China, patients currently need to pay attention to several core information.

As of now, the imported original drug of Brivaracetam has not been officially marketed in mainland China, which means that the original brand drug (usually produced by European pharmaceutical companies) has not yet been approved by the National Medical Products Administration for domestic circulation. However, there are already approved generic versions of brivaracetam on the market in China, providing patients with a legal treatment option. Domestic generic drugs are developed and produced by local pharmaceutical companies and are mainly provided through hospital prescriptions, specialist prescriptions and some online compliance pharmacy platforms. Patients can purchase them through formal channels, provided they have a doctor’s diagnosis certificate and prescription order. Since Brivaracetam is a prescription drug and may interact with other anti-epileptic drugs, patients are not allowed to buy the drug by themselves or change drugs at will, and must make adjustments under the guidance of a professional neurologist.

In overseas markets, the original drug of Brivaracetam has been officially launched by the Belgian company UCB under the trade name Briviact, and is currently available in many European countries. Common strengths are 50 mg tablets, with each bottle containing 60 tablets. This specification is common in overseas markets and is suitable for continuous use by patients with chronic epilepsy. However, the price is relatively high, and due to prescription restrictions and international transportation requirements, it is generally difficult for domestic patients to obtain it directly. Although some third-party cross-border drug purchasing platforms provide overseas drug purchasing services, due to uncertain factors such as drug sources, authenticity guarantees, customs clearance policies, and medical supervision, it is not recommended as the first choice, especially for diseases like epilepsy that require continuous monitoring of efficacy and side effects.

Reference materials:https://www.briviact.com/